Metabolic modulation: A new therapeutic target in treatment of heart failure

Chandrasekar Palaniswamy, William Michael Mellana, Dhana R. Selvaraj, Diwakar Mohan

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Treatment of heart failure involves management of risk factors and control of symptoms. Traditional management of heart failure involves the use of angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, diuretics, aldosterone antagonists, and digitalis. Metabolic modulators are a newer class of drugs that benefit these patients by modulating cardiac metabolism without altering hemodynamics. They have the potential to relieve symptoms in patients with refractory heart failure who are already on optimal medical therapy. These drugs increase glucose metabolism at the expense of free fatty acid metabolism, thereby enhancing efficient use of oxygen. This review discusses the role of 4 metabolic modulators drugs that could potentially be used for heart failure therapy: trimetazidine, ranolazine, perhexiline, and etomoxir.

Original languageEnglish (US)
Pages (from-to)e197-e201
JournalAmerican Journal of Therapeutics
Issue number6
StatePublished - Nov 1 2011


  • etomoxir
  • metabolic modulators
  • perhexiline
  • ranolazine
  • trimetazidine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Metabolic modulation: A new therapeutic target in treatment of heart failure'. Together they form a unique fingerprint.

Cite this